Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer
- Authors: Rapoport L.M1, Bezrukov E.A1, Kondrashina A.V1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia
- Issue: No 1 (2016)
- Pages: 58-61
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/282351
- ID: 282351
Cite item
Open Access
Access granted
Abstract
The relevance of drug treatment for prostate cancer increases with the number of patients who develop castration resistance. Currently, no unified treatment regimen for castration-resistant prostate cancer exists, but the standard treatment for these patients is continuous androgen deprivation therapy. This paper presents the experience of concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer. Ten patients with disease duration of 1.5 to 18 years and established castration resistance are currently being followed up. Nine of ten patients have long-term bone metastases, one patient has visceral metastases. The combination therapy produced a significant PSA decrease in nine patients and regression of bone lesions in two patients.
Full Text
About the authors
L. M Rapoport
I.M. Sechenov First Moscow State Medical University of Minzdrav of RussiaThe Department of Urology of Medical Faculty
E. A Bezrukov
I.M. Sechenov First Moscow State Medical University of Minzdrav of RussiaThe Department of Urology of Medical Faculty
A. V Kondrashina
I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia
Email: Kondrashina.ann@yandex.ru
The Department of Urology of Medical Faculty
References
- Состояние онкологической помощи населению России в 2010 году / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. M., 2011. М.: ФГУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России, 2011. 188 с.
- Mcleod D.G. Hormonal therapy: historical perspective to future directions. Urology. 2003;61:3-7.
- Schally A.V.,Arimura A.,Baba Y.,Nair R.M., Matsuo H.,Redding T.W., Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochemical and biophysical research communications. 1971;43(2):393-399.
- Heyns C.F., Simonin M.P., Grosgurin P., Schall R., Porchet H.C. South African Triptorelin Study G: Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU international. 2003;92(3):226-231.
- Shore N.D., Schimke L., Perzin A., Olsen S. Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration. Poster presentation AUA. 2012:12-16.
- Watson P.A., Arora V.K., Sawyers C.L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature reviews Cancer 2015.
- Gravanis I., Lopez A.S., Hemmings R.J., Jimenez J.C., Garcia-Carbonero R., Gallego I.G., Gimenez E.V., O'Connor D., Giuliani R., Salmonson T. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. The oncologist. 2013;18(9):1032-1042.
- Stein M.N., Goodin S., Dipaola R.S. Abiraterone in prostate cancer: a new angle to an old problem. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(7):1848-1854.
- Stein M.N., Patel N., Bershadskiy A., Sokoloff A. Singer E.A. Androgen synthesis inhibitors in the treatment of castrationresistant prostate cancer. Asian J. Androl. 2014; 16(3): 387-400.
- Sternberg C.N., Castellano D., Daugaard G., Geczi L., Hotte S.J., Mainwaring P.N., Saad F., Souza C., Tay H., Garrido J.M. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet Oncology. 2014;15(11):1263-1268.
Supplementary files
